GYRE insider transaction filings
GYRE THERAPEUTICS, INC. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-04. Screen GYRE transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-04 | 4 | Weston Claire — Director | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2026-08-04 | 4 | Kirkby Maxwell — Director | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2026-06-30 | 4 | Carmichael Gordon — Director | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2026-06-30 | 4 | Epstein David M. — Director | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2026-06-30 | 4 | Weng Dan — Director | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2026-06-30 | 4 | Parry Renate — Director | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2026-06-30 | 4 | Zhang Ping — Director | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2026-06-30 | 4 | Nussbaum Rodney L — Director | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | Ye Weiguo — Chief Operating Officer | Option exercise (M): 3,000 @ $0.75 · Sale (S): 3,000 @ $6.15 · Option exercise (M): 5,000 @ $0.75 · Sale (S): 5,000 @ $6.24 · Option exercise (M): 3,000 @ $0.75 · Sale (S): 3,000 @ $6.35 · +3 more | EDGAR |
| 2026-06-15 | 4 | Ye Weiguo — Chief Operating Officer | Option exercise (M): 2,800 @ $0.75 · Sale (S): 2,800 @ $6.17 · Option exercise (M): 2,800 (derivative) @ $0 | EDGAR |
| 2026-06-11 | 4 | Ye Weiguo — Chief Operating Officer | Option exercise (M): 14,500 @ $0.75 · Sale (S): 14,500 @ $6.14 · Option exercise (M): 6,418 @ $0.75 · Sale (S): 6,418 @ $6.21 · Option exercise (M): 14,500 (derivative) @ $0 · Option exercise (M): 6,418 (derivative) @ $0 | EDGAR |
| 2026-06-10 | 4 | Bergmann Joshua Benjamin — GC and Corporate Secretary | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2026-06-10 | 4 | Luo Ying — Chief Executive Officer, Director | Grant/award (A): 120,000 (derivative) @ $0 | EDGAR |
| 2026-06-08 | 4 | Ye Weiguo — Chief Operating Officer | Option exercise (M): 19,575 @ $0.75 · Sale (S): 19,575 @ $6.13 · Option exercise (M): 15,401 @ $0.75 · Sale (S): 15,401 @ $6.40 · Option exercise (M): 19,575 (derivative) @ $0 · Option exercise (M): 15,401 (derivative) @ $0 | EDGAR |
| 2026-05-27 | 4 | Ye Weiguo — Chief Operating Officer | Option exercise (M): 3,500 @ $0.75 · Sale (S): 3,500 @ $6.08 · Option exercise (M): 4,000 @ $0.75 · Sale (S): 4,000 @ $6.10 · Option exercise (M): 3,500 (derivative) @ $0 · Option exercise (M): 4,000 (derivative) @ $0 | EDGAR |
| 2026-05-22 | 4 | Ye Weiguo — Chief Operating Officer | Option exercise (M): 9,400 @ $0.75 · Sale (S): 9,400 @ $6.15 · Option exercise (M): 12,820 @ $0.75 · Sale (S): 12,820 @ $6.15 · Option exercise (M): 9,400 (derivative) @ $0 · Option exercise (M): 12,820 (derivative) @ $0 | EDGAR |
| 2026-05-20 | 4 | Zhang Ping — Director | Disposition to issuer (D): 250,000 (derivative) @ $0 | EDGAR |
| 2026-05-20 | 4 | Ye Weiguo — Chief Operating Officer | Option exercise (M): 200 @ $0.75 · Sale (S): 200 @ $6.62 · Option exercise (M): 9,120 @ $0.75 · Sale (S): 9,120 @ $6.37 · Option exercise (M): 200 (derivative) @ $0 · Option exercise (M): 9,120 (derivative) @ $0 | EDGAR |
| 2026-05-18 | 4 | Ye Weiguo — Chief Operating Officer | Option exercise (M): 15,580 @ $0.75 · Sale (S): 15,580 @ $6.91 · Option exercise (M): 13,100 @ $0.75 · Sale (S): 13,100 @ $6.65 · Option exercise (M): 15,580 (derivative) @ $0 · Option exercise (M): 13,100 (derivative) @ $0 | EDGAR |
| 2026-05-07 | 4 | Luo Ying — Chief Executive Officer, Director | Sale (S): 179 @ $8.01 · Sale (S): 10,136 @ $8.04 | EDGAR |
| 2026-05-06 | 4 | GNI Group Ltd. — 10% owner GNI USA, Inc. — 10% owner | Other (J): 458,120 (derivative) · Other (J): 2,143,706 (derivative) | EDGAR |
| 2026-05-06 | 4 | Eastling Thomas Wilson — Chief Financial Officer | Grant/award (A): 95,060 (derivative) @ $0 · Grant/award (A): 47,530 (derivative) @ $0 · Grant/award (A): 11,882 (derivative) @ $0 · Grant/award (A): 33,271 (derivative) @ $0 · Grant/award (A): 95,060 (derivative) @ $0 · Grant/award (A): 92,683 (derivative) @ $0 · +1 more | EDGAR |
| 2026-01-09 | 4 | Zhang Ping — Director | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2026-01-09 | 4 | Chen Ruoyu — Chief Financial Officer | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2025-08-26 | 4 | Weng Dan — Director | Grant/award (A): 52,000 (derivative) @ $0 | EDGAR |
| 2025-08-07 | 4 | Zhang Ping — Director | Grant/award (A): 250,000 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | Eastling Thomas Wilson — Director | Grant/award (A): 26,000 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | Epstein David M. — Director | Grant/award (A): 26,000 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | Nussbaum Rodney L — Director | Grant/award (A): 26,000 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | Parry Renate — Director | Grant/award (A): 26,000 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | Carmichael Gordon — Director | Grant/award (A): 26,000 (derivative) @ $0 | EDGAR |
| 2025-05-29 | 4 | Ma Songjiang — President, Director | Sale (S): 2,000 @ $10.28 · Sale (S): 558 @ $10.07 | EDGAR |
| 2025-05-28 | 4 | Zhang Ping — Director | Grant/award (A): 250,000 (derivative) @ $0 | EDGAR |
| 2025-05-27 | 4 | Ma Songjiang — President, Director | Sale (S): 2,000 @ $10.97 · Sale (S): 182 @ $10.24 | EDGAR |
| 2025-05-22 | 4 | Ma Songjiang — President, Director | Sale (S): 2,000 @ $11.25 · Sale (S): 2,000 @ $10.83 | EDGAR |
| 2025-05-20 | 4 | Ma Songjiang — President, Director | Sale (S): 2,000 @ $11.31 · Sale (S): 2,000 @ $11.11 | EDGAR |
| 2025-05-16 | 4 | Ma Songjiang — President, Director | Sale (S): 20 @ $11.30 · Sale (S): 2,000 @ $10.68 | EDGAR |
| 2025-05-14 | 4 | Ma Songjiang — President, Director | Sale (S): 2,000 @ $10.56 · Sale (S): 2,000 @ $11.37 | EDGAR |
| 2025-05-14 | 4 | Ye Weiguo — Chief Operating Officer | Option exercise (M): 50,000 @ $0.75 · Option exercise (M): 50,000 (derivative) @ $0 | EDGAR |
| 2025-04-25 | 4 | Ye Weiguo — Chief Operating Officer | Option exercise (M): 300,000 @ $0.75 · Option exercise (M): 200,000 @ $0.75 · Option exercise (M): 150,000 @ $0.75 · Option exercise (M): 300,000 (derivative) @ $0 · Option exercise (M): 200,000 (derivative) @ $0 · Option exercise (M): 150,000 (derivative) @ $0 | EDGAR |
| 2025-04-18 | 4 | Eastling Thomas Wilson — Director | Option exercise (M): 15,000 @ $6.93 · Option exercise (M): 15,000 (derivative) @ $0 | EDGAR |
| 2025-03-25 | 4 | Ma Songjiang — President, Director | Sale (S): 174 @ $10 | EDGAR |
| 2025-03-21 | 4 | Ma Songjiang — President, Director | Sale (S): 2,000 @ $10.13 · Sale (S): 2,000 @ $10.09 | EDGAR |
| 2025-03-19 | 4 | Ma Songjiang — President, Director | Sale (S): 2,000 @ $12.09 · Sale (S): 242 @ $10.24 | EDGAR |
| 2025-03-17 | 4 | Ma Songjiang — President, Director | Sale (S): 2,000 @ $11.80 · Sale (S): 2,000 @ $12.31 | EDGAR |
| 2025-03-13 | 4 | Ma Songjiang — President, Director | Sale (S): 2,000 @ $11.40 · Sale (S): 2,000 @ $11.74 | EDGAR |
| 2025-03-11 | 4 | Ye Weiguo — Chief Operating Officer | Grant/award (A): 300,000 (derivative) @ $0 | EDGAR |
| 2025-03-11 | 4 | Ma Songjiang — President, Director | Sale (S): 53 @ $13.03 · Sale (S): 41 @ $12.14 · Sale (S): 1,906 @ $10.13 · Sale (S): 2,000 @ $10.14 | EDGAR |
| 2025-03-07 | 4 | Ma Songjiang — President, Director | Sale (S): 2,000 @ $10.98 · Sale (S): 2,000 @ $10.80 | EDGAR |
| 2025-03-05 | 4 | Ma Songjiang — President, Director | Sale (S): 2,000 @ $11.23 · Sale (S): 2,000 @ $10.86 | EDGAR |
Recent 8-K events — GYRE THERAPEUTICS, INC.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-07 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-16 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-15 | 8-K/A | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-16 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-06-02 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-14 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-12 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-07 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-04 | 8-K | 2.01 — Completion of Acquisition or Disposition of Assets 3.02 — Unregistered Sales of Equity Securities 3.03 — Material Modification to Rights of Security Holders 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-17 | 8-K/A | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=GYRE returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →